Altering certain provisions of law authorizing certain activity by manufacturers of investigational drugs, biological products, or devices under the Right to Try Act to apply to manufacturers of certain individualized investigational treatments; altering the definition of "eligible patient" under the Right to Try Act to include individuals who have life-threatening or severely debilitating illnesses, rather than only individuals who have terminal illnesses; etc.